Jacob P Laubach

Jacob P Laubach

UNVERIFIED PROFILE

Are you Jacob P Laubach?   Register this Author

Register author
Jacob P Laubach

Jacob P Laubach

Publications by authors named "Jacob P Laubach"

Are you Jacob P Laubach?   Register this Author

76Publications

2696Reads

9Profile Views

Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.

J Geriatr Oncol 2019 May 22;10(3):486-489. Epub 2018 Nov 22.

Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18794068183034
Publisher Site
http://dx.doi.org/10.1016/j.jgo.2018.10.010DOI Listing
May 2019

Ixazomib for the treatment of multiple myeloma.

Expert Opin Pharmacother 2018 Dec 13;19(17):1949-1968. Epub 2018 Nov 13.

g Hematology & Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1528229DOI Listing
December 2018

The power of proteasome inhibition in multiple myeloma.

Expert Rev Proteomics 2018 12 14;15(12):1033-1052. Epub 2018 Nov 14.

b Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2018.1543595DOI Listing
December 2018

Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis.

JAMA Cardiol 2018 09;3(9):865-870

Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Heart & Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2018.2093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233639PMC
September 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Br J Haematol 2018 05 10;181(4):433-446. Epub 2018 May 10.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15116DOI Listing
May 2018

Practical Considerations for Antibodies in Myeloma.

Am Soc Clin Oncol Educ Book 2018 May;38:667-674

From the Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; International Myeloma Foundation, North Hollywood, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_205443DOI Listing
May 2018

74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis.

Clin Biochem 2018 Jan 24;51:97-100. Epub 2017 May 24.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States; Dana-Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2017.05.013DOI Listing
January 2018

The proteasome and proteasome inhibitors in multiple myeloma.

Cancer Metastasis Rev 2017 12;36(4):561-584

Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9707-8DOI Listing
December 2017

Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.

Mayo Clin Proc 2017 Dec;92(12):1800-1805

Cardiac Amyloidosis Program, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2017.09.016DOI Listing
December 2017

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.

Pharmacol Res 2017 03 21;117:185-191. Epub 2016 Nov 21.

Clínica Universidad de Navarra, Universidad de Navarra, CIMA, IDISNA, Av. de Pio XII, 36, 31008 Pamplona, Navarra, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2016.11.020DOI Listing
March 2017

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol 2017 Mar 1;10(3):229-237. Epub 2017 Feb 1.

a Department of Hematologic Malignancies , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1280388DOI Listing
March 2017

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.

Expert Rev Clin Pharmacol 2016 26;9(1):35-48. Epub 2015 Oct 26.

d CIMA, IDISNA , Clínica Universidad de Navarra , Pamplona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2016.1096773DOI Listing
June 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Future Oncol 2015 ;11(8):1153-68

Division of Hematologic Malignancy, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.9DOI Listing
February 2016

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

Blood 2016 Feb 2;127(6):681-95. Epub 2015 Dec 2.

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-646810DOI Listing
February 2016

Panobinostat for the Treatment of Multiple Myeloma.

Clin Cancer Res 2015 Nov 11;21(21):4767-73. Epub 2015 Sep 11.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0530DOI Listing
November 2015

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

N Engl J Med 2015 Sep 26;373(13):1207-19. Epub 2015 Aug 26.

From the Department of Hematology, University Medical Center Utrecht, Utrecht (H.M.L., M.C.M., N.W.C.J.D.), and the Department of Hematology, VU University Medical Center, Amsterdam (H.M.L., N.W.C.J.D.) - both in the Netherlands; Vejle Hospital and University of Southern Denmark, Vejle (T.P., J.K.), and Rigshospitalet and University of Copenhagen (P.G., U.L.) and Genmab (N.L., S.L., L.B., N.B.), Copenhagen - all in Denmark; Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.P.L., P.G.R.); Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.), and Skåne University Hospital and Lund University, Lund (M.H.) - all in Sweden; Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy (A.P.); Janssen Research and Development, Spring House, PA (T.A., C.M.U., A.K.S.); and Janssen Research and Development, Raritan, NJ (I.K., J.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506348DOI Listing
September 2015

Resolving the daratumumab interference with blood compatibility testing.

Transfusion 2015 Jun 12;55(6 Pt 2):1545-54. Epub 2015 Mar 12.

Blood Bank, Department of Pathology, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.13069DOI Listing
June 2015

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.

Clin Cancer Res 2015 Jun 15;21(12):2660-2. Epub 2015 Apr 15.

Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3190DOI Listing
June 2015

Management of relapsed multiple myeloma after autologous stem cell transplant.

Biol Blood Marrow Transplant 2015 May 31;21(5):793-8. Epub 2015 Jan 31.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.12.026DOI Listing
May 2015

Ibrutinib in previously treated Waldenström's macroglobulinemia.

N Engl J Med 2015 Apr;372(15):1430-40

From the Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute (S.P.T., C.K.T., K.M., D.W., G.Y., Y.C., L.X., C.J.P., S.K., I.G., J.J.C., J.P.L., Z.R.H.), Harvard Medical School (S.P.T., G.Y., Y.C., S.R., J.C.A., N.L.H., I.G., J.J.C., J.P.L.), Department of Pathology, Brigham and Women's Hospital (S.R., J.C.A.), Department of Pathology, Massachusetts General Hospital (N.L.H.), and Department of Pathology, Boston University Medical Center (Z.R.H.) - all in Boston; Memorial Sloan Kettering Cancer Center, New York (R.G., K.V.A., M.L.P.); and Stanford University Medical Center, Stanford (G.V., J.L.Z., R.H.A.), and Pharmacyclics, Sunnyvale (Z.S., J.L., M.C., F.C., T.G.) - both in California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1501548DOI Listing
April 2015

Scleromyxedema with histology resembling granuloma annulare.

Dermatol Online J 2014 Dec 31;21(3). Epub 2014 Dec 31.

Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
December 2014

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):255-61. Epub 2014 Nov 18.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2014.1.255DOI Listing
December 2014

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.

Clin Cancer Res 2014 Aug 23;20(15):3955-61. Epub 2014 Jun 23.

Massachusetts General Hospital Cancer Center; Harvard Medical School, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0434DOI Listing
August 2014

Daratumumab granted breakthrough drug status.

Expert Opin Investig Drugs 2014 Apr 20;23(4):445-52. Epub 2014 Feb 20.

Medical Oncologist, Dana-Farber Cancer Institute, Harvard Medical School, Je Lipper Multiple Myeloma Center , 450 Brookline Ave., Mayer 556, Boston, MA 02215 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2014.889681DOI Listing
April 2014

Having a heavy heart: approaches to infiltrative cardiomyopathy.

Circulation 2014 Apr;129(16):1703-11

From Cardiovascular Medicine (P.R.L., N.K.L.) and Department of Medicine (B.A.B.), Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA (P.R.L., B.A.B., J.P.L., N.K.L.); Dana Farber Cancer Institute, Boston, MA (J.P.L.); and Cardiology, Veterans Affairs Boston Healthcare System, Boston, MA (N.K.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.113.006932DOI Listing
April 2014

Current strategies for treatment of relapsed/refractory multiple myeloma.

Expert Rev Hematol 2014 Feb 29;7(1):97-111. Epub 2014 Jan 29.

Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.882764DOI Listing
February 2014

Kidney disease and multiple myeloma.

Clin J Am Soc Nephrol 2013 Nov 18;8(11):2007-17. Epub 2013 Jul 18.

Nephrology Division and Transplantation Center, Massachusetts General Hospital, Boston, Massachusetts;, †Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, ‡Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.12231212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817918PMC
November 2013

Phase transitions in human IgG solutions.

J Chem Phys 2013 Sep;139(12):121904

Materials Processing Center, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.4811345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108626PMC
September 2013

Pathological crystallization of human immunoglobulins.

Proc Natl Acad Sci U S A 2012 Aug 30;109(33):13359-61. Epub 2012 Jul 30.

Materials Processing Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1211723109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421172PMC
August 2012

Management of myeloma-associated renal dysfunction in the era of novel therapies.

Expert Rev Hematol 2012 Feb;5(1):51-66; quiz 67-8

Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.11.72DOI Listing
February 2012

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

Am J Hematol 2011 Jul 31;86(7):573-8. Epub 2011 May 31.

The Multiple Myeloma/Waldenstrom's Macroglobulinemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.22048
Publisher Site
http://dx.doi.org/10.1002/ajh.22048DOI Listing
July 2011

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

J Clin Oncol 2011 May 11;29(14):1916-23. Epub 2011 Apr 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.34.0760
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.34.0760DOI Listing
May 2011

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Expert Rev Hematol 2011 Feb;4(1):51-60

Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.10.83DOI Listing
February 2011

The spectrum of kidney involvement in lymphoma: a case report and review of the literature.

Am J Kidney Dis 2010 Dec 16;56(6):1191-6. Epub 2010 Sep 16.

Nephrology Division, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2010.07.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222147PMC
December 2010

The evolution and impact of therapy in multiple myeloma.

Med Oncol 2010 Jun 19;27 Suppl 1:S1-6. Epub 2010 Feb 19.

Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-010-9442-2DOI Listing
June 2010

Finding the right academic job.

Hematology Am Soc Hematol Educ Program 2009 :729-33

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2009.1.729DOI Listing
March 2010

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

J Natl Compr Canc Netw 2010 Feb;8 Suppl 1:S4-S12

Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/8/Suppl_1/S-4.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2010.0115DOI Listing
February 2010

Bortezomib in the management of multiple myeloma.

Cancer Manag Res 2009 Sep 8;1:107-17. Epub 2009 Sep 8.

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004671PMC
http://dx.doi.org/10.2147/cmar.s4555DOI Listing
September 2009

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Leuk Lymphoma 2009 May;50(5):694-702

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190902866732DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133638PMC
May 2009